146 related articles for article (PubMed ID: 35365198)
1. Population-based estimates of age-specific cumulative risk of breast cancer for pathogenic variants in ATM.
Renault AL; Dowty JG; Steen JA; Li S; Winship IM; Giles GG; Hopper JL; Southey MC; Nguyen-Dumont T
Breast Cancer Res; 2022 Apr; 24(1):24. PubMed ID: 35365198
[TBL] [Abstract][Full Text] [Related]
2. Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family Registry.
Bernstein JL; Teraoka S; Southey MC; Jenkins MA; Andrulis IL; Knight JA; John EM; Lapinski R; Wolitzer AL; Whittemore AS; West D; Seminara D; Olson ER; Spurdle AB; Chenevix-Trench G; Giles GG; Hopper JL; Concannon P
Hum Mutat; 2006 Nov; 27(11):1122-8. PubMed ID: 16958054
[TBL] [Abstract][Full Text] [Related]
3. Rare variants in the ATM gene and risk of breast cancer.
Goldgar DE; Healey S; Dowty JG; Da Silva L; Chen X; Spurdle AB; Terry MB; Daly MJ; Buys SM; Southey MC; Andrulis I; John EM; ; ; Khanna KK; Hopper JL; Oefner PJ; Lakhani S; Chenevix-Trench G
Breast Cancer Res; 2011 Jul; 13(4):R73. PubMed ID: 21787400
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer screening implications of risk modeling among female relatives of ATM and CHEK2 carriers.
Weidner AE; Liggin ME; Zuniga BI; Tezak AL; Wiesner GL; Pal T
Cancer; 2020 Apr; 126(8):1651-1655. PubMed ID: 31967672
[TBL] [Abstract][Full Text] [Related]
5. Penetrance of ATM Gene Mutations in Breast Cancer: A Meta-Analysis of Different Measures of Risk.
Marabelli M; Cheng SC; Parmigiani G
Genet Epidemiol; 2016 Jul; 40(5):425-31. PubMed ID: 27112364
[TBL] [Abstract][Full Text] [Related]
6. Ataxia-telangiectasia gene (
Jerzak KJ; Mancuso T; Eisen A
Curr Oncol; 2018 Apr; 25(2):e176-e180. PubMed ID: 29719442
[TBL] [Abstract][Full Text] [Related]
7. Cancer risks associated with heterozygous ATM loss of function and missense pathogenic variants based on multigene panel analysis.
Laitman Y; Nielsen SM; Bernstein-Molho R; Heald B; Hatchell KE; Esplin ED; Friedman E
Breast Cancer Res Treat; 2022 Nov; 196(2):355-361. PubMed ID: 36094610
[TBL] [Abstract][Full Text] [Related]
8. Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer.
Reiner AS; Robson ME; Mellemkjær L; Tischkowitz M; John EM; Lynch CF; Brooks JD; Boice JD; Knight JA; Teraoka SN; Liang X; Woods M; Shen R; Shore RE; Stram DO; Thomas DC; Malone KE; Bernstein L; Riaz N; Woodward W; Powell S; Goldgar D; Concannon P; ; Bernstein JL
J Natl Cancer Inst; 2020 Dec; 112(12):1275-1279. PubMed ID: 32119081
[TBL] [Abstract][Full Text] [Related]
9. ATM c.7570G>C is a high-risk allele for breast cancer.
Kankuri-Tammilehto M; Tervasmäki A; Kraatari-Tiri M; Rahikkala E; Pylkäs K; Kuismin O
Int J Cancer; 2023 Feb; 152(3):429-435. PubMed ID: 36161273
[TBL] [Abstract][Full Text] [Related]
10. Germline Pathogenic Variants in the Ataxia Telangiectasia Mutated (
Hall MJ; Bernhisel R; Hughes E; Larson K; Rosenthal ET; Singh NA; Lancaster JM; Kurian AW
Cancer Prev Res (Phila); 2021 Apr; 14(4):433-440. PubMed ID: 33509806
[TBL] [Abstract][Full Text] [Related]
11. Dominant negative ATM mutations in breast cancer families.
Chenevix-Trench G; Spurdle AB; Gatei M; Kelly H; Marsh A; Chen X; Donn K; Cummings M; Nyholt D; Jenkins MA; Scott C; Pupo GM; Dörk T; Bendix R; Kirk J; Tucker K; McCredie MR; Hopper JL; Sambrook J; Mann GJ; Khanna KK
J Natl Cancer Inst; 2002 Feb; 94(3):205-15. PubMed ID: 11830610
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Breast Cancer Risk Assessment for
Gallagher S; Hughes E; Kurian AW; Domchek SM; Garber J; Probst B; Morris B; Tshiaba P; Meek S; Rosenthal E; Roa B; Slavin TP; Wagner S; Weitzel J; Gutin A; Lanchbury JS; Robson M
JCO Precis Oncol; 2021 Jun; 5():. PubMed ID: 34322652
[TBL] [Abstract][Full Text] [Related]
13. Cancer risks and mortality in heterozygous ATM mutation carriers.
Thompson D; Duedal S; Kirner J; McGuffog L; Last J; Reiman A; Byrd P; Taylor M; Easton DF
J Natl Cancer Inst; 2005 Jun; 97(11):813-22. PubMed ID: 15928302
[TBL] [Abstract][Full Text] [Related]
14. Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene.
Hsu FC; Roberts NJ; Childs E; Porter N; Rabe KG; Borgida A; Ukaegbu C; Goggins MG; Hruban RH; Zogopoulos G; Syngal S; Gallinger S; Petersen GM; Klein AP
JAMA Oncol; 2021 Nov; 7(11):1664-1668. PubMed ID: 34529012
[TBL] [Abstract][Full Text] [Related]
15. Genetic variants in ATM, H2AFX and MRE11 genes and susceptibility to breast cancer in the polish population.
Podralska M; Ziółkowska-Suchanek I; Żurawek M; Dzikiewicz-Krawczyk A; Słomski R; Nowak J; Stembalska A; Pesz K; Mosor M
BMC Cancer; 2018 Apr; 18(1):452. PubMed ID: 29678143
[TBL] [Abstract][Full Text] [Related]
16. Frequency of the ATM IVS10-6T-->G variant in Australian multiple-case breast cancer families.
Lindeman GJ; Hiew M; Visvader JE; Leary J; Field M; Gaff CL; Gardner RJ; Trainor K; Cheetham G; Suthers G; Kirk J
Breast Cancer Res; 2004; 6(4):R401-7. PubMed ID: 15217508
[TBL] [Abstract][Full Text] [Related]
17. Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.
Renault AL; Mebirouk N; Fuhrmann L; Bataillon G; Cavaciuti E; Le Gal D; Girard E; Popova T; La Rosa P; Beauvallet J; Eon-Marchais S; Dondon MG; d'Enghien CD; Laugé A; Chemlali W; Raynal V; Labbé M; Bièche I; Baulande S; Bay JO; Berthet P; Caron O; Buecher B; Faivre L; Fresnay M; Gauthier-Villars M; Gesta P; Janin N; Lejeune S; Maugard C; Moutton S; Venat-Bouvet L; Zattara H; Fricker JP; Gladieff L; Coupier I; ; ; ; Chenevix-Trench G; Hall J; Vincent-Salomon A; Stoppa-Lyonnet D; Andrieu N; Lesueur F
Breast Cancer Res; 2018 Apr; 20(1):28. PubMed ID: 29665859
[TBL] [Abstract][Full Text] [Related]
18. The association between ATM variants and risk of breast cancer: a systematic review and meta-analysis.
Moslemi M; Moradi Y; Dehghanbanadaki H; Afkhami H; Khaledi M; Sedighimehr N; Fathi J; Sohrabi E
BMC Cancer; 2021 Jan; 21(1):27. PubMed ID: 33402103
[TBL] [Abstract][Full Text] [Related]
19. Bayesian meta-analysis of penetrance for cancer risk.
Ruberu TLM; Braun D; Parmigiani G; Biswas S
Biometrics; 2024 Mar; 80(2):. PubMed ID: 38819308
[TBL] [Abstract][Full Text] [Related]
20. First international workshop of the ATM and cancer risk group (4-5 December 2019).
Lesueur F; Easton DF; Renault AL; Tavtigian SV; Bernstein JL; Kote-Jarai Z; Eeles RA; Plaseska-Karanfia D; Feliubadaló L; ; Arun B; Herold N; Versmold B; Schmutzler RK; ; Nguyen-Dumont T; Southey MC; Dorling L; Dunning AM; Ghiorzo P; Dalmasso BS; Cavaciuti E; Le Gal D; Roberts NJ; Dominguez-Valentin M; Rookus M; Taylor AMR; Goldstein AM; Goldgar DE; ; Stoppa-Lyonnet D; Andrieu N
Fam Cancer; 2022 Apr; 21(2):211-227. PubMed ID: 34125377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
